Asset Details
Do you wish to reserve the book?
Zastosowanie produktu leczniczego terapii zaawansowanej - wyjątku szpitalnego a eksperyment leczniczy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Zastosowanie produktu leczniczego terapii zaawansowanej - wyjątku szpitalnego a eksperyment leczniczy
Do you wish to request the book?
Zastosowanie produktu leczniczego terapii zaawansowanej - wyjątku szpitalnego a eksperyment leczniczy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Zastosowanie produktu leczniczego terapii zaawansowanej - wyjątku szpitalnego a eksperyment leczniczy
2024
Overview
The article presents considerations based on the regulations of EU and Polish law regarding the manufacture and use of advanced therapy medicinal products – hospital exemptions. The author discusses the EU source of the ATMP-HE regulation, its function and the purpose of introducing it into EU law, and then the relationship of this regulation to the Polish regulation on the therapeutic experiment. In the author's opinion, on the basis of the current legal status, there is no justification for the position according to which an advanced therapy medicinal product – hospital exemption is such a legally separate concept, or even a legal institution, that the national regulation does not apply to it. This is because this position is not only inconsistent with EU and national regulations, but also results in shifting to the patient the burden of risk of using this product without any control and responsibility. The author expressed the position that de lege lata the use of an advanced therapy medicinal product - hospital exemption should be qualified as a therapeutic experiment, to which the limits of admissibility of its performance also apply. The author presents the effects of recognizing the use of ATMP-HE as the therapeutic experiment and the effects of adopting a different position. In addition, the article contains considerations on the groundlessness of equating the use of ATMP-HE with off-label use and compassionate use. The author also formulated de lege ferenda postulates.
Publisher
Instytut Filozofii Uniwersytetu Jagiellońskiego,Institute of Philosophy, Jagiellonian University
Subject
